Daphne Zohar
CIK: 0001727388
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)2 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPTX
Seaport Therapeutics, Inc.
DirectorOfficer
Discretionary Trading P&L
Holdings
About Zohar Daphne
Zohar Daphne (SEC CIK 0001727388) files insider reports with the SEC as Chief Executive Officer of Seaport Therapeutics, Inc. (SPTX).
Signal8 holds 1 ownership filing by Zohar Daphne, a Form 4, filed on May 4, 2026. Those filings report 2 transactions, the latest on Apr 30, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Zohar Daphne's filings is in BOSTON, MA.
Recent filings by Zohar Daphne
- Apr 30, 2026: Grants or awards of SPTX derivative securities (2 lines, Form 4, code A).
Other insiders filing for Seaport Therapeutics, Inc. (SPTX)
- HOMBACH ROBERT J., Director
- GAP Coinvestments CDA, L.P., Director
- General Atlantic (SP), L.P., Director
- PureTech Health plc, 10% Owner
- HEALY JAMES, Director
- White Lauren, Chief Financial Officer